Abstract
Short sequence amino acids or oligopeptides have recently garnered attention for use as treatments for a myriad of dermatologic disorders due to their ability to effect and modulate various biological processes in the epidermis and dermis, rendering them promising candidates as medical and cosmeceutical therapeutics. Major advantages include their relative ease of synthesis and multitude of modifications that can be applied to enhance potency, affinity, specificity, hydrophilicity or hydrophobicity and cytotoxicity. Given the photoprotective effects of eumelanin on skin, there has been substantial interest in developing agents, particularly α-MSH analogs, that can induce ‘sunless tanning’ helping reduce risk of melanoma and non-melanoma skin cancer. In this mini review, we present some of the recent and leading peptide modulators of melanogenesis with relevant clinical data and medical indications. Short sequence oligopeptides with tyrosinase inhibitory activity that can significantly reduce hyperpigmentation, as well α-MSH analogs that can enhance eumelanogenesis, are currently being clinically tested for treatment of erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, actinic keratosis, and “sunless tanning”. Success in developing such products can help reduce the incidence of skin cancer, one that surpasses that of all other human cancers combined.
Keywords: α-MSH analogs, hyperpigmentation, hypopigmentation, melanocortin 1 receptor, melanogenesis, tyrosinase.
Current Topics in Medicinal Chemistry
Title:Minireview: Peptide Analogs and Short Sequence Oligopeptides as Modulators of Skin Pigmentation
Volume: 14 Issue: 12
Author(s): Anan Abu Ubeid and Basil M. Hantash
Affiliation:
Keywords: α-MSH analogs, hyperpigmentation, hypopigmentation, melanocortin 1 receptor, melanogenesis, tyrosinase.
Abstract: Short sequence amino acids or oligopeptides have recently garnered attention for use as treatments for a myriad of dermatologic disorders due to their ability to effect and modulate various biological processes in the epidermis and dermis, rendering them promising candidates as medical and cosmeceutical therapeutics. Major advantages include their relative ease of synthesis and multitude of modifications that can be applied to enhance potency, affinity, specificity, hydrophilicity or hydrophobicity and cytotoxicity. Given the photoprotective effects of eumelanin on skin, there has been substantial interest in developing agents, particularly α-MSH analogs, that can induce ‘sunless tanning’ helping reduce risk of melanoma and non-melanoma skin cancer. In this mini review, we present some of the recent and leading peptide modulators of melanogenesis with relevant clinical data and medical indications. Short sequence oligopeptides with tyrosinase inhibitory activity that can significantly reduce hyperpigmentation, as well α-MSH analogs that can enhance eumelanogenesis, are currently being clinically tested for treatment of erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, actinic keratosis, and “sunless tanning”. Success in developing such products can help reduce the incidence of skin cancer, one that surpasses that of all other human cancers combined.
Export Options
About this article
Cite this article as:
Ubeid Abu Anan and Hantash M. Basil, Minireview: Peptide Analogs and Short Sequence Oligopeptides as Modulators of Skin Pigmentation, Current Topics in Medicinal Chemistry 2014; 14 (12) . https://dx.doi.org/10.2174/1568026614666140601221519
DOI https://dx.doi.org/10.2174/1568026614666140601221519 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Genetically Modified Bacteria to Modulate Adaptive Immunity
Current Gene Therapy Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Recent Advances of Poly(ether-ether) and Poly(ether-ester) Block Copolymers in Biomedical Applications
Current Drug Metabolism Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma
Anti-Cancer Agents in Medicinal Chemistry